Chief investigator - Dr Steve Knapper, Cardiff University
A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)
Amount awarded: £207,671
Award start date: 01 Jul 2015
Recruitment start date: 16 Jan 2017
Award duration: 3 years

Chronic myelomonocytic leukaemia (CMML) is an uncommon form of blood cancer that causes a build-up of cells called monocytes in the bone marrow and blood. It mainly affects older people, so most people with CMML are unsuitable for bone marrow transplant therapy, and there are currently very few other treatment options.

Tefinostat works by inhibiting proteins (enzymes) called histone deacetylases - cells need these enzymes to grow and divide. Drugs that block these enzymes are called histone deacetylase inhibitors, or HDAC inhibitors. Tefinostat selectively targets enzymes that are found in monocytes.

The aims of the trial are to:

  • Determine the tolerability and safety of tefinostat in people with CMML
  • To assess the clinical efficacy of tefinostat in CMML

You may be eligible to join this trial if:

  • You have newly-diagnosed or previously-treated CMML
  • You are 18 years of age or older